

**PHOSPONOCARBOXYLATE COMPOUNDS FOR TREATING ABNORMA**

Publication number: JP7507318 (T)

Publication date: 1995-08-10

Inventor(s):

Applicant(s):

Classification:

- international: A61K31/66; A61K31/675; A61K31/685; A61P3/00; A61P3/14; A61P19/10; A61P29/00; A61P43/00; C07F9/38; C07F9/553; C07F9/572; C07F9/576; C07F9/58; C07F9/59; C07F9/60; C07F9/6506; C07F9/6512; C07F9/6561; A61K31/66; A61K31/675; A61K31/683; A61P3/00; A61P19/00; A61P29/00; A61P43/00; C07F9/00; (IPC1-7): C07F9/38; A61K31/66; A61K31/675; A61K31/685; C07F9/572; C07F9/58; C07F9/59; C07F9/6506

Also published as:

- WO9324131 (A1)
- US5731299 (A)
- SK143694 (A3)
- PL174726 (B1)
- NZ253852 (A)

[more >>](#)

- European: C07F9/38A1; C07F9/38A1; C07F9/38A1; C07F9/38A1; C07F9/38A1; C07F9/38A1; C07F9/38A1W; C07F9/38A6M; C07F9/38A6U; C07F9/553A7; C07F9/572E; C07F9/572G; C07F9/572K4; C07F9/576V; C07F9/58G; C07F9/58R; C07F9/59G; C07F9/59R; C07F9/60; C07F9/6506E; C07F9/6506G; C07F9/6512R; C07F9/6561


Application number: JP19930500737T 19930527

Priority number(s): WO1993US04993 19930527; US19920891490 19920529; US19920890885 19920529; US19920890886 19920529; US19920891309 19920529; US19920891355 19920529; US19920891487 19920529

Abstract not available for JP 7507318 (T)

Abstract of corresponding document: WO 9324131 (A1)

The present invention relates to compositions comprising pharmaceutically-acceptable carriers and a phosphonocarboxylate, or a pharmaceutically-acceptable salt thereof, having a structure according to formula (I), wherein (1) A is selected from the group consisting of hydrogen; halogen; SR<1>; R<2>SR<1>; amino; hydroxy; and substituted or unsubstituted C1-C8 alkyl; (2) B is (a) NH<sub>2</sub>; etc. or (B) A and B are covalently linked together with C\* to form a monocyclic or bicyclic ring having structure alpha . The present invention further relates to novel phosphonocarboxylates and pharmaceutically-acceptable salts thereof. Finally, the present invention relates to methods for treating or preventing pathological conditions characterized by abnormal calcium and phosphate metabolism in humans or other mammals. This method comprises administering to a human or other mammal in need of such treatment of a safe and effective amount of a compound or composition of the present invention.



Data supplied from the esp@cenet database — Worldwide